Hepatitis B Vaccine (Recombinant) Completed Phase 4 Trials for Seroprevalence / Viral Hepatitis B / Immune Response Prevention

IndicationsStatusPurposePhase
CompletedPrevention4
clinicaltrials.gov IdentifierTitleDrugs
NCT01861613Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students
NCT00984139Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination
NCT01138098Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in Previously Vaccinated Children
NCT00186836Efficacy Study of Combined Hepatitis A and Hepatitis B Vaccine to Protect Against Hepatitis B in Hemodialysis Patients
NCT00197158Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response
NCT00240500Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers
NCT00335881Persistence of the Immune Response to Hepatitis B in 4-6 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib
NCT00356564Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib
NCT00456625Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.
NCT00657657Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine